Tools and Technologies for Breakthrough in Heart Therapies- in short TECHNOBEAT is part of the Horizon 2020 funding programme of the European Commission.
TECHNOBEAT is rooted in the extensive, interdisciplinary research by basic and applied scientists at the LEBAO and clinicians at the HTTG (Department of Cardiac, Thoracic, Transplantation and Vascular Surgery) on the MHH campus. Substantial recent progress in i) human induced pluripotent stem cell (hiPSC) reprogramming and tailored genetic engineering (RG Martin), ii) novel methods for hiPSC mass production in controlled bioreactors including cardiac (RG Zweigerdt) and endothelial differentiation (RG Olmer), as well as iii) animal models of heart failure and cell therapies (RGs Haverich, Cebotari, Martens) paved the way to the EU Horizon2020 funded, trans European Network TECHNOBEAT.
The interdisciplinary TECHNOBEAT consortium consists of renowned experts from six European countries and Israel working in the fields of cell therapy, tissue engineering, stem cell processing and clinical translation. Together we aim to provide new treatment options for patients suffering from heart failure due to the loss of heart muscle tissue following myocardial infarction (heart attack).
This Project is funded by the European Union‘s Horizon 2020 research and innovation programme
under grant agreement no. 668724
TECHNOBEAT Consortium meets for second General Assembly
Hosted by the Consortium Partner DASGIP-Eppendorf on February 16th-17th, 2017 the event focused on progress of the first 12 months of work. The principal investigators presented the general overview of their work packages, supplemented by an in-depth overview of data and results to date by the researchers.
Further to the discussion of results, upcoming activities and additional points of intersection and cooperation were identified and agreed on.
A highlight was the presence of two members of the TECHNOBEAT Scientific Advisory Board who also held expert advisor key note speeches:
Prof. Loren J. Field, Indiana University School of Medicine:
Current status of cell based heart repair
Prof. Paul J. Fairchild, Sir William Dunn School of Pathology, University of Oxford:
Immunological barriers to cell replacement therapy in animal models and prospects for the induction of immunological tolerance